The way we communicate and interact digitally is constantly changing. Unfortunately, fraud and scams are the order of the day ...

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

With the modality now in early clinical trials, experts say more efficiency, broader editing capabilities and delivery ...

QuEra Computing Inc. has started a collaboration with Deloitte Tohmatsu Group intended to advance the quantum industry in ...

Biometric Derived Keys introduced by Tech5 enable encrypted sharing of identity data through selective disclosure while ...

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

Scleral lenses demonstrated safety and efficacy for treating ocular surface disease and irregular cornea/refractive ...

Discover how Peloton overcame overexpansion challenges with strategic restructuring, boosting FY 2025 EBITDA guidance and ...

Mims Davies MP's weekly column on becoming a Patron for the Greenaway Foundation, Westminster after Recess, joining Ashurst ...

Trump’s executive order to recognise only two sexes—male and female—has triggered a tragic dilemma of revealing less and ...

Strong evidence for ALS often comes from familial forms of the disease, where specific gene mutations— for example in the ...